TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Recommendation of "Buy" from Brokerages

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) have been assigned an average recommendation of "Buy" from the five ratings firms that are presently covering the stock, MarketBeat reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have covered the stock in the last year is $7.80.

A number of research firms recently issued reports on TCRX. Barclays lowered their target price on TScan Therapeutics from $14.00 to $3.00 and set an "overweight" rating on the stock in a research report on Friday, March 7th. Morgan Stanley reaffirmed an "overweight" rating and issued a $10.00 target price on shares of TScan Therapeutics in a research report on Friday, March 14th. HC Wainwright lowered their price target on TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Needham & Company LLC reissued a "buy" rating and set a $9.00 price target on shares of TScan Therapeutics in a research report on Tuesday, April 8th. Finally, Wedbush reissued an "outperform" rating and set a $7.00 price target on shares of TScan Therapeutics in a research report on Tuesday, May 6th.

Insider Buying and Selling

In other TScan Therapeutics news, major shareholder Lynx1 Capital Management Lp acquired 1,200,000 shares of the stock in a transaction dated Tuesday, May 20th. The stock was purchased at an average cost of $1.20 per share, with a total value of $1,440,000.00. Following the transaction, the insider now owns 7,946,141 shares in the company, valued at approximately $9,535,369.20. The trade was a 17.79% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. 4.35% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On TScan Therapeutics

A number of hedge funds have recently added to or reduced their stakes in TCRX. SG Americas Securities LLC boosted its stake in shares of TScan Therapeutics by 31.2% in the 4th quarter. SG Americas Securities LLC now owns 20,415 shares of the company's stock worth $62,000 after buying an additional 4,852 shares during the last quarter. Tocqueville Asset Management L.P. boosted its stake in shares of TScan Therapeutics by 26.8% in the 4th quarter. Tocqueville Asset Management L.P. now owns 260,870 shares of the company's stock worth $793,000 after buying an additional 55,140 shares during the last quarter. Prudential Financial Inc. purchased a new position in shares of TScan Therapeutics in the 4th quarter worth approximately $32,000. JPMorgan Chase & Co. boosted its stake in shares of TScan Therapeutics by 109.9% in the 4th quarter. JPMorgan Chase & Co. now owns 66,756 shares of the company's stock worth $203,000 after buying an additional 34,951 shares during the last quarter. Finally, Wellington Management Group LLP boosted its stake in shares of TScan Therapeutics by 5.2% in the 4th quarter. Wellington Management Group LLP now owns 132,895 shares of the company's stock worth $404,000 after buying an additional 6,550 shares during the last quarter. Institutional investors and hedge funds own 82.83% of the company's stock.

TScan Therapeutics Stock Down 3.7%

NASDAQ:TCRX opened at $1.55 on Friday. TScan Therapeutics has a 12-month low of $1.02 and a 12-month high of $9.08. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $87.72 million, a P/E ratio of -1.46 and a beta of 0.98. The stock's fifty day simple moving average is $1.45 and its 200-day simple moving average is $2.13.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.02. The firm had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.62 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. Equities research analysts expect that TScan Therapeutics will post -1.12 earnings per share for the current year.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.